Members of Congress recently reintroduced the Cancer Drug Parity Act (H.R. 4385) in the U.S. House of Representatives. The bill would ensure patient cost-sharing for oral and other self-administered anticancer drugs is no less favorable than for traditional intravenous (IV) medication administered in an office setting.
Oral cancer drugs can provide significant clinical advantages over more traditional IV medications, and in some instances, may represent the only or best treatment option for a patient. Some health insurance plans, however, impose significantly higher cost-sharing requirements (such as copayments and coinsurance) for oral cancer therapies. Such measures often create significant financial barriers to accessing treatment – even though some oral medications may lower the overall cost of care.
ASCO has long been a strong supporter of oral parity legislation to alleviate the financial burdens on patients with cancer. The Society urges lawmakers to support oral parity legislation and ensure patients have access to the highest-quality cancer treatment.
Stay connected to ASCO in Action for updates, in addition to news, advocacy, and analysis on cancer policy.